Skip to Content

CBD Goes Mainstream with Jump to CVS and Walgreens

By Matt McCallMar 28, 2019

When I tell people that marijuana stocks may be one of the best investment opportunities of their lifetimes, I think their minds usually go to the more dramatic story of “legal weed” — like the “cannabis cafés” popping up everywhere from West Hollywood to Alaska.

However, I’ve long thought that its non-psychoactive cousin, cannabidiol (CBD), could be the real growth opportunity. In fact, I prepared a CBD research report for my Investment Opportunities subscribers last October that I titled, The Huge Marijuana Story Everyone is Missing. It’s still true.

But don’t take my word for it. CVS Health (CVS) and Walgreens (WBA) apparently see the same thing.

In the last week, both CVS and Walgreens have announced that they will start selling CBD in several different states. (Specifically, the topical creams, etc., for pain relief.) We’re talking about huge pharmacy brands; CVS stores in particular are ubiquitous in major U.S. cities — and now that it’s operating Target (TGT) pharmacies, that goes for the suburbs, too.

So for CBD companies like the one we’ll look at in a minute, access to these massive distribution networks is a big deal. According to the Brightfield Group, we can expect hemp-derived CBD sales at chained retailers to go from zero in 2018 to $13.9 billion in 2022. That’ll be about two-thirds of an overall $22 billion market.

But maybe an even bigger deal is that CVS was the first “big box” retailer to jump on the bandwagon.

CVS is increasingly conservative with its offerings when it comes to pain meds. Most folks can’t get more than seven days’ worth of opioids. And even each day’s dose is limited, depending on the strength of what’s prescribed.

So, the fact that CVS is selling CBD really underscores what I’ve been saying all along:

CBD is one of the most beneficial compounds you can get, without the nasty side effects of drugs. It’s now a part of my normal health and wellness activities — I take it every night before I go to bed. Over the years, I have turned friends, family, and colleagues on to the benefits of CBD and seen positive changes in their lives as well.

I know people who suffer from chronic pain. And, of course, the standard treatment is opioids. The biggest reason for that is simple — the power of global pharmaceutical conglomerates. Unfortunately, we now see the tragic consequences every day.

We are now losing 130 people a day to opioids in the United States, according to the CDC. And many turn from pills to heroin, causing those overdose rates to skyrocket.

How many people overdose on non-synthetic CBD? Zero. There aren’t even any major side effects.

With the recently passed 2018 U.S. Farm Bill that legalized industrial hemp, I expect we’ll start to see the research and education we need to have CBD largely replace opioids across the country.

The impact of that would be enormous. In 2016, the U.S. opioid market was valued at $23 billion. I expect a large amount of that to shift to alternatives in the next few years, most notably CBD, so we’re talking about billions of dollars.

And it’s also interesting to note that CVS is far and away the leading pharmacy when it comes to prescription revenues. It brings in almost as much as its next two competitors — Walgreens and Cigna (CI)/Express Scripts — combined.

So, CVS could be an especially key player in the growth story of medical marijuana, in addition to the Curaleaf (CURLF) branded topical CBD the company will now be selling.

When major retailers get involved in formerly “niche” products, the sky is usually the limit.

Impact on Cannabis Stocks

With the kind of numbers we’re looking at, you know I’ve been hard at work figuring out the best way to make money off of this massive trend.

Sales projections — and the opportunity to steal market share from Big Pharma opioids — make marijuana stocks a compelling growth story. And, specifically, CBD stocks.

Curaleaf took off on the CVS partnership news, by as much as 49%.

Charlotte’s Web Holdings (CWBHF) did well, too… and it’s a pure play on hemp-CBD. It’s also my pick for InvestorPlace’s Best Stocks for 2019 contest.

In researching CBD stocks when few others were, Charlotte’s Web stood out as the clear leader. It’s set to grow more than 100% annually over the next five years, as it’s uniquely qualified to benefit from the trends I just laid out.

The company gets its name from a little girl named Charlotte who was suffering almost constant grand mal seizures, but saw them largely disappear after trying CBD oil. (I’ve covered Charlotte’s story before, and you really ought to check it out. It’s truly amazing.)

These days, Charlotte’s Web is a $1.8 billion company by market cap, and its quarterly revenue trends are powerful:

As I mentioned when I named Charlotte’s Web as my Best Stock pick, the company is really ramping up its production… so in the future, when CVS or one of its peers is looking for CBD, they’ll come calling on Charlotte’s Web.

Wall Street is starting to catch on, driving the stock more than 68% higher since I recommended it in Investment Opportunities just six months ago. I’m glad to have spotted it early.

Throughout my career, I’ve found that investing in the early innings is key. Now, marijuana and CBD stocks are one of the key areas I’m turning to for early-stage profits.

P.S. Investing early in big trends can mean great opportunities in companies that go public. That’s certainly true with marijuana.

But, you don’t want to buy any old IPO. You want to see that the company can make money first. Plus, it’s crucial to get the timing right.

That’s what I designed my Cannabis Cash Calendar system to do specifically for marijuana IPOs. And our first recommendation has already more than doubled in less than four months!

It’s not too late to get in on our new opportunity. On April 4th — next Thursday — I am planning to release my next Cannabis Cash Calendar recommendation. You can get exclusive access to it as soon as it’s released to my Investment Opportunities readers. Click here to learn more about this opportunity and how to get on the list to be notified.

Maybe you don’t know much more about marijuana stocks than what I’ve said here. That’s fine. Even if you’ve never bought a stock before, you’ll want to check this out. I’d say take a small stake…and you could potentially see that multiply over the next 12 months. Click here to for more on this incredible story.

Learn where Matt McCall sees
huge investment opportunities right now:

Autonomous Vehicles: A Once-in-a-Generation Opportunity

Self-driving cars – aka “autonomous vehicles” (AVs) – represent one of the biggest investment opportunities of the next 25 years. This innovation will transform huge portions of our economy and create trillion dollar ripple effects through time. It will create huge new winners in short periods of time. It will demolish losers in equally short periods of time. It’s critical that you stay on the right side of this trend. Learn more here.

Why the Legal Marijuana Industry is Set to Grow More than 10-Fold

Marijuana has been outlawed most everywhere for decades… but now a wave of legalization is starting to sweep the world. This will create massive new markets and massive stock market winners. Learn more here.

2019 Will Be Sports Betting’s Biggest Year Yet

If I had to make one bet for 2019 it would be that betting is going to be big. The Supreme Court’s May 14 ruling cleared the way for states to allow sports gambling. And in my 25 years of investing experience, I honestly cannot remember many things that come close to magnitude of the investing opportunity that opened up to us. Massive amounts of money are involved in sports betting, and I expect massive amounts of money will be made, too. Learn more here.

Don't miss out on the incredible megatrends that are shaping today's market. Gain access to the most powerful market insights and stock advice from Matt McCall absolutely FREE. Join Today!